David Drewry

David Drewry

SGC UNC

Drewry

David Drewry

(919) 962-5349

Biography

David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.

2024

Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.

Rinderle CH, Baker CV, Lagarde CB, Nguyen K, Al-Ghadban S, Matossian MD, Hoang VT, Martin EC, Collins-Burow BM, Ali S, Drewry DH, Burow ME, Bunnell BA

Anticancer Drugs. 2024-12-13 . 36(1):39-48 .doi: 10.1097/CAD.0000000000001658

PMID: 39671264

Convergence on CaMK4: a key modulator of autism-associated signaling pathways in neurons.

Kaiser J, Risteska A, Muller AG, Sun H, Lei B, Nay K, Means AR, Cousin MA, Drewry DH, Oakhill JS, Kemp BE, Hannan AJ, Berk M, Febbraio MA, Gundlach AL, Hill-Yardin EL, Scott JW

Biol Psychiatry. 2024-10-24 . .doi: 10.1016/j.biopsych.2024.10.012

PMID: 39442785

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.

Ong HW, Yang X, Smith JL, Taft-Benz S, Howell S, Dickmander RJ, Havener TM, Sanders MK, Brown JW, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

Molecules. 2024-9-14 . 29(17): .doi: 10.3390/molecules29174158

PMID: 39275006

Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.

Rinderle CH, Baker CV, Lagarde CB, Nguyen K, Al-Ghadban S, Matossian MD, Hoang VT, Martin EC, Collins-Burow BM, Ali S, Drewry DH, Burow ME, Bunnell BA

Anticancer Drugs. 2024-8-21 . .doi: 10.1097/CAD.0000000000001658

PMID: 39163320

Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.

Bashore FM, Min SM, Chen X, Howell S, Rinderle CH, Morel G, Silvaroli JA, Wells CI, Bunnell BA, Drewry DH, Pabla NS, Ultanir SK, Bullock AN, Axtman AD

ACS Med Chem Lett. 2024-8-8 . 15(8):1325-1333 .doi: 10.1021/acsmedchemlett.4c00219

PMID: 39140040

Illumination of understudied ciliary kinases.

Flax RG, Rosston P, Rocha C, Anderson B, Capener JL, Durcan TM, Drewry DH, Prinos P, Axtman AD

Front Mol Biosci. 11.07.2024. 11:1352781 .doi: 10.3389/fmolb.2024.1352781

PMID: 38523660

More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication.

Ong HW, Yang X, Smith JL, Dickmander RJ, Brown JW, Havener TM, Taft-Benz S, Howell S, Sanders MK, Capener JL, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

J Med Chem. 2024-7-3 . .doi: 10.1021/acs.jmedchem.4c00962

PMID: 38959455

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.

Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL

Eur J Med Chem. 2024-4-2 . 271:116357 .doi: 10.1016/j.ejmech.2024.116357

PMID: 38636130

2023

Characterization of 2,4-Dianilinopyrimidines Against Five P. falciparum Kinases PfARK1, PfARK3, PfNEK3, PfPK9, and PfPKB.

Ong HW, de Silva C, Avalani K, Kwarcinski F, Mansfield CR, Chirgwin M, Truong A, Derbyshire ER, Zutshi R, Drewry DH

ACS Med Chem Lett. 2023-12-14 . 14(12):1774-1784 .doi: 10.1021/acsmedchemlett.3c00354

PMID: 38116430

SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.

Tiek D, Wells CI, Schröder M, Song X, Alamillo-Ferrer C, Goenka A, Iglesia R, Lu M, Hu B, Kwarcinski F, Sintha P, de Silva C, Hossain MA, Picado A, Zuercher W, Zutshi R, Knapp S, Riggins RB, Cheng SY, Drewry DH

Curr Res Chem Biol. 2023-11-27 . 3: .doi: 10.1016/j.crchbi.2023.100045

PMID: 38009092